2 results
Approved WMOCompleted
The purpose of the current study is to determine whether LHW090 displays the clinical safety and efficacy profile to support further development for resistant hypertension.
Approved WMORecruiting
To compare the 120 mg once daily (QD) dose and 200 mg QD dose of MK*6482with respect to objective response rate (ORR) based on Response Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review (BICR).